- Trial phase
- Approved
- Time to market
- Already marketed (FDA-approved 2006 for alcohol dependence; 2010 for opioid dependence)
- Why 4/10
- VIVITROL is already FDA-approved and marketed with no pending regulatory decision (PDUFA or pivotal readout) for this drug. The next hard catalyst is the scheduled Teva generic entry on January 15, 2027 (~6 months away), a known revenue headwind rather than a binary event. VIVITROL accounts for ~29% of Alkermes' $1.56B total revenue, but the company is diversifying (LUMRYZ, alixorexton, ARISTADA, LYBALVI), so this single drug is no longer make-or-break.
Watch for the January 2027 Teva generic entry, this will pressure Vivitrol's ~$457M annual revenue stream. Monitor the antitrust lawsuit (Value Drug, filed Oct 2025) which could accelerate generic competition. The stock has run ~97% from its 52-week low and trades near its high; consider whether the diversification story (LUMRYZ, alixorexton orexin agonist in Phase 3) adequately offsets the Vivitrol cliff.
Price Chart
Executive Summary
VIVITROL (extended-release injectable naltrexone) is Alkermes' flagship commercial product, generating $457.3M in 2024 revenue (14% YoY growth, ~29% of Alkermes' total revenue). FDA-approved since 2006 for alcohol dependence and 2010 for opioid dependence, it is a once-monthly opioid antagonist injection that reduces cravings. Its key overhang is the January 2027 Teva generic entry, established by a 2023 patent settlement. An October 2025 antitrust lawsuit alleges Alkermes illegally blocked generic competition. Alkermes is actively diversifying via the Avadel/LUMRYZ acquisition and advancing alixorexton (orexin agonist) in Phase 3 for narcolepsy, reducing Vivitrol's singular importance to the investment thesis.
How It Works
VIVITROL is a once-monthly injection of naltrexone, a drug that blocks opioid receptors in the brain. This reduces cravings for alcohol and opioids and prevents the euphoric "high" if someone relapses, helping patients maintain sobriety. Unlike methadone or buprenorphine, it is not an opioid itself and has no abuse potential.
Trial Status
VIVITROL is an approved commercial product with no active pivotal trials. Teva has a license to launch a generic version beginning January 15, 2027 per an August 2023 settlement agreement.
The Two-Sided Case
Upcoming Catalysts
- January 15, 2027: Teva generic VIVITROL launch (known, scheduled event)
- Ongoing: Antitrust class-action lawsuit (Value Drug), any summary judgment or settlement could accelerate resolution
- Q3/Q4 2026 & early 2027: Alixorexton Phase 3 narcolepsy data readouts (key for Alkermes diversification thesis)
- Quarterly earnings: Vivitrol revenue trajectory as generic entry approaches
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Alkermes plc. 8-K ALKS ·Originating report